Abstracts Open Access
Copyright ©The Author(s) 2000. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 15, 2000; 6(Suppl3): 57-57
Published online Sep 15, 2000. doi: 10.3748/wjg.v6.iSuppl3.57
Research on the antitumor effect of Zhenhuang injection
Jin-Jie Xu, Xiao-Hu Xu, Department of Pathology and Pathophysiology of Medical College, Shantou University, Shantou 515031, Guangdong Province, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Xiao-Hu Xu, Department of Pathology and Pathophysiology of Medical College, Shantou University, 22 Xinling Road, Shantou 515031, Guangdong Province, China. jjxu@pub.Shantou.gd.cn
Telephone: 754-8900433 Fax: 754-8941747
Received: March 4, 2000
Revised: May 10, 2000
Accepted: July 10, 2000
Published online: September 15, 2000

Abstract

AIM: To study the antitumor effect of Zhenhuang Injection (ZHI) on the mice bearing transplanted tumor.

METHODS: The solid type of H22 transplantation hepotocarci noma, ascitic type of S-180 sarcoma and ascitic type of LII malignant lymphoma of mice were treated at three doses (crude drug 1.25 g/kg, 2.5 g/kg, 5.0 g/kg of body weight) of ZHI. The solid tumor group and ascitic tumor group were injected intravenously and intraperitoneally. The experiment was repeated three times.

RESULTS: The tumor-inhibition rate of H22 hepatocarcinoma in moderate and large doses was 30.23%-35.67% (P < 0.01) and 46.36%-54.07% (P < 0.01) respectively; the survival rate of ascitic type of S-180 sarcoma and ascitic type of L-II malignant lymphoma in large dose group was 77.23%-86.91% (P < 0.01) and 75.42%-79.04% (P < 0.01), respectively.

CONCLUSION: ZHI has a certain tumor inhibiting effect. Under the tolerant dose, the effect improves with the increase of dose.

Key Words: Neoplasms/drug effects; Drug screening assays, antitumor; Liver neoplasms/drug therapy; Sarcoma/drug therapy; Lymphoma/drug therapy; Neoplasms/experimental

Footnotes

E- Editor: Zhang FF

$[References]